Nuwellis (NASDAQ:NUWE) Issues Quarterly Earnings Results, Misses Expectations By $2.84 EPS

Nuwellis (NASDAQ:NUWE) posted its earnings results on Thursday. The company reported ($26.64) earnings per share for the quarter, missing the consensus estimate of ($23.80) by ($2.84), Zacks reports. The business had revenue of $1.97 million for the quarter, compared to analysts’ expectations of $2.42 million. Nuwellis had a negative return on equity of 32,351.83% and a negative net margin of 214.90%.

Here are the key takeaways from Nuwellis’ conference call:

• Second-quarter revenue rose 14% year over year to $1.97 million, with U.S. revenue up 17%; first-half revenue increased 20% to $4.37 million, driven by stronger U.S. growth and increased console placements.
• Gross margin improved substantially to 76% from 56% a year ago, benefiting from higher average selling prices, favorable product mix, and the transition to contract manufacturing.
• Nuwellis sold nine consoles in the quarter and 24 in the first half, versus five in the first half of 2025, while expanding pediatric programs and targeting greater recurring circuit utilization in pediatrics and adult critical care.
• The company plans to submit an FDA application in the fourth quarter to expand Aquadex use to patients weighing at least 5 kilograms, while Clarity Prime is targeted for launch in 2027 and new critical-care capabilities remain under development.
• Despite the improved gross margin, Nuwellis reported a $4.8 million net loss and had only $3.9 million in cash at quarter-end; subsequent financings and warrant exercises raised approximately $6.7 million but may increase dilution.

Nuwellis Trading Down 7.8%

Shares of Nuwellis stock traded down $0.11 during trading on Thursday, reaching $1.30. The company’s stock had a trading volume of 683,993 shares, compared to its average volume of 8,940,867. The company has a 50-day moving average price of $3.17 and a two-hundred day moving average price of $34.52. Nuwellis has a fifty-two week low of $1.25 and a fifty-two week high of $235.20. The firm has a market cap of $2.42 million, a PE ratio of -0.00 and a beta of 0.31.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on NUWE shares. Wall Street Zen upgraded shares of Nuwellis to a “hold” rating in a report on Saturday, July 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Nuwellis in a research report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Nuwellis presently has an average rating of “Sell”.

About Nuwellis

Nuwellis (NASDAQ:NUWE) is a medical technology company focused on developing therapies and devices to manage fluid overload in patients with cardiorenal and cardiovascular conditions. The company’s core business revolves around designing, manufacturing and marketing the Aquadex™ FlexFlow® System, a gentle ultrafiltration device intended to remove excess fluid in patients with acute decompensated heart failure, cardiorenal syndrome and other fluid?overload disorders. By providing an alternative to traditional diuretic therapy, Nuwellis aims to improve patient outcomes and reduce hospital stays.

The Aquadex FlexFlow System operates by drawing blood through a low?shear filter and returning it to the patient, allowing precise control of fluid removal at the bedside outside of an intensive care setting.